Leela Limited Company accounts

COMPANY REGISTRATION NUMBER: 03130924

Leela Limited

Unaudited Financial Statements

31 March 2025

Leela Limited

Financial Statements

Year ended 31 March 2025

Contents	Page

Directors' report	1

Statement of income and retained earnings	2

Statement of financial position	3

Notes to the financial statements	5

Leela Limited

Directors' Report

Year ended 31 March 2025

The directors present their report and the unaudited financial statements of the company for the year ended 31 March 2025 .

Directors

The directors who served the company during the year were as follows:

Dr J T Anglin
Dr G N Anglin
Ms K Srinivas

Other matters

On the 30th of January 2017 the company entered into a service agreement with BARDOC. This agreement between Leela Ltd and BARDOC passes the responsibility for the operation of the company's NHS PMS contract to BARDOC in return for 99% of the income from the said PMS contract.

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 2 December 2025 and signed on behalf of the board by:

Dr J T Anglin

Registered office:

18/19 Salmon Fields

Business Village

Royton

Oldham

OL2 6HT

Leela Limited

Statement of Income and Retained Earnings

Year ended 31 March 2025

	2025	2024
Note	£	£
Turnover	748,448	672,924

Cost of sales	673,433	636,375
	---------	---------
Gross profit	75,015	36,549

Administrative expenses	46,801	64,906
Other operating income	36,466	33,331
	--------	--------
Operating profit	64,680	4,974

Other interest receivable and similar income		98	–
		--------	--------
Profit before taxation	4	64,778	4,974

Tax on profit	13,504	1,069
	--------	-------
Profit for the financial year and total comprehensive income	51,274	3,905
	--------	-------

Retained earnings at the start of the year	1,234,527	1,230,622
	------------	------------
Retained earnings at the end of the year	1,285,801	1,234,527
	------------	------------

All the activities of the company are from continuing operations.

Leela Limited

Statement of Financial Position

31 March 2025

	2025		2024
Note	£	£	£

Fixed assets

Tangible assets	6	794,748	795,081
Investments	7	38,336	38,336
		---------	---------
		833,084	833,417

Current assets

Debtors	8	368,042	367,532
Cash at bank and in hand		115,626	74,920
		---------	---------
		483,668	442,452

Creditors: amounts falling due within one year	9	30,851		41,242
		---------		---------
Net current assets			452,817	401,210
			------------	------------
Total assets less current liabilities			1,285,901	1,234,627
			------------	------------
Net assets			1,285,901	1,234,627
			------------	------------

Capital and reserves

Called up share capital	100	100
Profit and loss account	1,285,801	1,234,527
	------------	------------
Shareholders funds	1,285,901	1,234,627
	------------	------------

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Leela Limited

Statement of Financial Position (continued)

31 March 2025

These financial statements were approved by the board of directors and authorised for issue on 2 December 2025 , and are signed on behalf of the board by:

Dr J T Anglin

Company registration number: 03130924

Leela Limited

Notes to the Financial Statements

Year ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 18/19 Salmon Fields, Business Village, Royton, Oldham, OL2 6HT.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

	Goodwill	-	10% straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Pant & Machinery	-	25% reducing balance
Fixtures & Fittings	-	20% reducing balance
Office Equipment	-	20% reducing balance

Investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

Investments in associates

Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.

Investments in joint ventures

Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.

Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

4. Profit before taxation

Profit before taxation is stated after charging:

	2025	2024
	£	£
Depreciation of tangible assets	333	650
	----	----

5. Intangible assets

	Goodwill
	£
Cost
At 1 April 2024 and 31 March 2025	228,000
	---------
Amortisation
At 1 April 2024 and 31 March 2025	228,000
	---------
Carrying amount
At 31 March 2025	–
	---------
At 31 March 2024	–
	---------

6. Tangible assets

	Land and buildings	Plant and machinery	Fixtures and fittings	Equipment	Total
	£	£	£	£	£
Cost
At 1 April 2024 and 31 March 2025	793,408	3,918	27,916	25,351	850,593
	---------	-------	--------	--------	---------
Depreciation
At 1 April 2024	–	3,918	27,408	24,186	55,512
Charge for the year	–	–	101	232	333
	---------	-------	--------	--------	---------
At 31 March 2025	–	3,918	27,509	24,418	55,845
	---------	-------	--------	--------	---------
Carrying amount
At 31 March 2025	793,408	–	407	933	794,748
	---------	-------	--------	--------	---------
At 31 March 2024	793,408	–	508	1,165	795,081
	---------	-------	--------	--------	---------

7. Investments

	Other investments other than loans
	£
Cost
At 1 April 2024 and 31 March 2025	111,833
	---------
Impairment
At 1 April 2024 and 31 March 2025	73,497
	---------

Carrying amount
At 31 March 2025	38,336
	---------
At 31 March 2024	38,336
	---------

8. Debtors

	2025	2024
	£	£
Other debtors	368,042	367,532
	---------	---------

9. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	10,824	35,158
Corporation tax	13,407	1,069
Other creditors	6,620	5,015
	--------	--------
	30,851	41,242
	--------	--------

10. Directors' advances, credits and guarantees

Included within creditors due within one year are loans from directors totalling £3,202 (2024: £1,775) on which no interest is being charged. The loans are repayable in full or in part on demand.

11. Related party transactions

The company was under the control of Dr J T Anglin , a director and members of his close family throughout the current and previous year. Dr J T Anglin is personally interested in 50% (2024 - 50%) of the company's share capital. In addition, his wife controls in aggregate a further 50% (2024 - 50%) of the company's issued share capital. No transactions with related parties were undertaken such as are required to be disclosed under Financial Reporting Standard 8.